Tg Therapeutics (TGTX) Share-based Compensation (2011 - 2026)

Tg Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 32.77% year-over-year to $21.2 million in Q1 2026; TTM through Mar 2026 was $21.2 million, a 61.32% decrease from a year earlier, with the FY2025 full-year figure at $64.7 million, up 39.6% from the prior year.
• Share-based Compensation grew to $21.2 million in Q1 2026 per TGTX's latest filing, from $15.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $42.5 million in Q3 2025 and bottomed at -$975000.0 in Q2 2022.
• The 5-year median for Share-based Compensation is $12.7 million (2024), against an average of $14.7 million.
• Across the five-year window, Share-based Compensation sank 105.98% in 2022 and soared 1493.03% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $36.6 million in 2022, then plunged by 66.44% to $12.3 million in 2023, then rose by 28.22% to $15.7 million in 2024, then fell by 0.51% to $15.7 million in 2025, then surged by 35.45% to $21.2 million in 2026.
• Per Business Quant, the three latest TGTX Share-based Compensation figures stand at $21.2 million (Q1 2026), $15.7 million (Q4 2025), and $42.5 million (Q3 2025).